In the last decade, several antiangiogenic drugs based on the VEGF-VEGFR2 signaling axis (the most highly recognized target for current antiangiogenic therapy), including bevacizumab (a monoclonal antibody against VEGF), ramucirumab (a monoclonal antibody against VEGFR2) and apatinib (a tyrosine kinase inhibitor targeting VEGFR2), have been introduced for GC treatment. Here, VEGFA is linked to gastric cancer.